

FMHL/SE/BM/NOV'25

November 06, 2025

To,
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001

Scrip Code: 523696

Subject: Outcome of Board Meeting in accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015 ("SEBI Listing Regulations") this is to inform you that the Board of Directors of the Company at its meeting held today i.e. Thursday, November 06, 2025, inter-alia, considered and approved the following matter: -

Financial Results

Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2025 ("**Quarterly Results**").

Accordingly, please find enclosed herewith Un-Audited Standalone and Consolidated Financial Results of the Company along with limited review report given by the Statutory Auditor of the Company for the quarter and half year ended September 30, 2025.

The Board Meeting commenced at 11.10 AM and concluded at 02:25 PM.

This is for your information and record please.

Thanking You,
For **Fortis Malar Hospitals Limited**

VINTI
VERMA

Digitally signed
by VINTI VERMA
Date: 2025.11.06
14:31:46 +05'30'

Vinti Verma
Company Secretary & Compliance Officer
ICSI Membership No. A44528

Encl.: as above

FORTIS MALAR HOSPITALS LIMITED

Regd. Office: Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062 **Tel:** +0172-4692222 **Fax:** +91 172 5096002

CIN: L85110PB1989PLC045948 **Email:** secretarial.malar@malarhospitals.in

Website: www.fortismalarhospital.com

Limited Review Report on unaudited consolidated financial results of Fortis Malar Hospitals Limited for the quarter ended 30 September 2025 and year to date results for the period from 1 April 2025 to 30 September 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Fortis Malar Hospitals Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Fortis Malar Hospitals Limited (hereinafter referred to as "the Parent"), and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30 September 2025 and year to date results for the period from 1 April 2025 to 30 September 2025 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:
 - a. Fortis Malar Hospitals Limited
 - b. Fortis Healthcare Research Foundation (Formerly known as "Malar Stars Medicare Limited")

Limited Review Report (Continued)

Fortis Malar Hospitals Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We draw attention to Note 7 to the Statement which explains that consequent to sale of business operations through a slump sale transaction, the Parent ceases to have any business operations. While there is no visibility of commencing any new business operations in the future, the Parent's management and Board of Directors is currently evaluating various corporate restructuring options for the future possible course of actions for the Parent and is progressing with the finalisation of plan. However, the Parent believes that it has sufficient cash and cash equivalent and other bank balances to settle its obligations as and when they fall due, and it believes that it would be able to meet its financial requirements for the foreseeable future based on the current cash position and projected cash flows. Accordingly, these unaudited consolidated financial results have been prepared on a going concern basis.

Our conclusion is not modified in respect of this matter.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Varun Kumar Tyagi

Partner

Gurugram

06 November 2025

Membership No.: 518152

UDIN: 25518152BMOVGS2856

Limited Review Report on unaudited standalone financial results of Fortis Malar Hospitals Limited for the quarter ended 30 September 2025 and year to date results for the period from 1 April 2025 to 30 September 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Fortis Malar Hospitals Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Fortis Malar Hospitals Limited (hereinafter referred to as "the Company") for the quarter ended 30 September 2025 and year to date results for the period from 1 April 2025 to 30 September 2025 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Limited Review Report (*Continued*)

Fortis Malar Hospitals Limited

5. We draw attention to Note 7 to the Statement which explains that consequent to sale of business operations through a slump sale transaction, the Company ceases to have any business operations. While there is no visibility of commencing any new business operations in the future, the Company's management and Board of Directors is currently evaluating various corporate restructuring options for the future possible course of actions for the Company and is progressing with the finalisation of plan. However, the Company believes that it has sufficient cash and cash equivalent and other bank balances to settle its obligations as and when they fall due, and it believes that it would be able to meet its financial requirements for the foreseeable future based on the current cash position and projected cash flows. Accordingly, these unaudited standalone financial results have been prepared on a going concern basis.

Our conclusion is not modified in respect of this matter.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Varun Kumar Tyagi

Partner

Gurugram

06 November 2025

Membership No.: 518152

UDIN: 25518152BMOVGR2869

(All figures except equity share capital)

No.	Particulars	Standalone		Standalone		Standalone Year ended		Consolidated		Consolidated		Consolidated Year ended	
		Quarter ended		Six months ended		March 31, 2025		Quarter ended		Six months ended		March 31, 2025	
		September 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024	(Unaudited)	(Unaudited)	September 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024	March 31, 2025	March 31, 2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1	Income												
	a) Grant income	51.72	460.72	51.72	460.72	271.72	271.72	2.50	460.72	55.72	460.72	512.44	512.44
	b) Other income (refer note 10)	51.72	460.72	51.72	460.72	271.72	271.72	54.22	460.72	55.72	460.72	512.44	512.44
	Total Income	103.44	921.44	103.44	921.44	543.44	543.44	76.72	921.44	111.44	921.44	1024.88	1024.88
2	Expenses												
	a) Purchase of medical consumables and drugs	-	-	-	-	-	-	-	-	-	-	-	-
	b) Changes in inventories of medical consumables and drugs	-	-	-	-	-	-	-	-	-	-	-	-
	c) Employee benefits expense	2.20	2.21	2.20	2.21	40.76	40.76	2.20	2.21	0.23	2.21	4.41	4.41
	d) Finance costs	-	-	-	-	1.02	1.02	-	-	0.02	0.02	-	-
	e) Depreciation and amortization expenses	-	-	-	-	-	-	-	-	-	-	-	-
	f) Project expenses	-	-	-	-	-	-	-	-	-	-	-	-
	g) Other expenses	34.51	27.64	34.51	27.64	171.35	171.35	35.11	27.64	46.64	27.64	2.47	2.47
	Total expenses	36.71	29.85	36.71	29.85	112.13	112.13	37.31	29.85	46.87	29.85	51.18	51.18
3	Profit / (loss) before exceptional items and taxes (1-2)	15.01	430.87	15.01	430.87	35.59	35.59	14.44	430.87	8.83	430.87	214.91	214.91
4	Exceptional items	-	-	-	-	-	-	-	-	-	-	-	-
5	Profit / (loss) after exceptional items and before tax (3+4)	15.01	430.87	15.01	430.87	35.59	35.59	14.44	430.87	8.83	430.87	214.91	214.91
6	Tax expense	13.02	13.22	13.02	13.22	17.59	17.59	13.02	13.22	-	13.22	17.61	17.61
	- Current tax	13.02	13.22	13.02	13.22	17.59	17.59	13.02	13.22	-	13.22	17.61	17.61
	- Earlier year income tax	-	-	-	-	-	-	-	-	-	-	-	-
	- Deferred tax charged (credit)	-	-	-	-	-	-	-	-	-	-	-	-
7	Profit / (loss) after tax (5-6)	1.99	417.65	1.99	417.65	22.59	22.59	1.42	417.65	8.83	417.65	197.30	197.30
	Other comprehensive income / (loss) (net of tax)	-	-	-	-	-	-	-	-	-	-	-	-
	Other comprehensive income / (loss) (net of tax)	-	-	-	-	-	-	-	-	-	-	-	-
	Items that will not be reclassified subsequently in the statement of profit and loss	-	-	-	-	-	-	-	-	-	-	-	-
8	Other comprehensive income / (loss) (net of tax)	-	-	-	-	-	-	-	-	-	-	-	-
9	Total comprehensive income / (loss) for the period / year (7+8)	1.99	417.65	1.99	417.65	22.59	22.59	1.42	417.65	8.83	417.65	197.30	197.30
	- Owners of the company	1.99	417.65	1.99	417.65	22.59	22.59	1.42	417.65	8.83	417.65	197.30	197.30
	- Non-controlling interest	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10	Basic EPS (Rs.10 each)	1.99	417.65	1.99	417.65	22.59	22.59	1.42	417.65	8.83	417.65	197.30	197.30
11	Reserves excluding revaluation reserves - other equity	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70
12	Earnings Per Share (EPS) based on (7) above (of Rs.10 each)	1.99	417.65	1.99	417.65	22.59	22.59	1.42	417.65	8.83	417.65	197.30	197.30
	- Basic	1.99	417.65	1.99	417.65	22.59	22.59	1.42	417.65	8.83	417.65	197.30	197.30
	- Diluted	0.01	2.23	0.01	2.23	0.01	0.01	0.01	2.22	0.05	2.23	0.01	0.01



FORTIS MALAR HOSPITALS LIMITED (CIN: L85110PB1989PLC045948)

Regd. Office: Fortis Hospital, Sector 62, Phase – VIII, Mohali-160062

Tel Numbers: 0172 5096001 & Tele Fax No : 0172 5096002

Website: www.fortismalarhospitals.com; Email: secretarial.malar@malarhospitals.in

STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2025

Notes:

1. STANDALONE AND CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

(Rs. in lakhs)

Particulars	Standalone		Consolidated	
	As at	As at	As at	As at
	September 30, 2025 (Unaudited)	March 31, 2025 (Audited)	September 30, 2025 (Unaudited)	March 31, 2025 (Audited)
ASSETS				
Non-current assets				
(a) Financial assets				
(i) Investment in subsidiary	5.00	5.00	-	-
(b) Other tax assets (net)	250.73	250.73	272.04	272.04
Total non-current assets	255.73	255.73	272.04	272.04
Current assets				
(a) Financial assets				
(i) Trade receivables	-	-	2.50	-
(ii) Cash and cash equivalents	21.24	10.80	27.39	20.24
(iii) Bank balances other than (i) above	1,846.63	1,759.23	1,846.63	1,759.23
(iv) Other financial assets	1,567.38	1,631.54	1,567.38	1,631.54
(b) Other current assets	3.22	0.15	3.22	0.15
Total current assets	3,438.47	3,401.72	3,447.12	3,411.16
Total assets	3,694.20	3,657.45	3,719.16	3,683.20
EQUITY AND LIABILITIES				
Equity				
(a) Equity share capital	1,875.70	1,875.70	1,875.70	1,875.70
(b) Other equity	1,540.35	1,120.71	1,561.90	1,145.21
Total equity	3,416.05	2,996.41	3,437.60	3,020.91
Liabilities				
Current liabilities				
(a) Financial liabilities				
(i) Trade payables				
Total outstanding dues of micro enterprises and small enterprises	2.56	-	2.56	-
Total outstanding dues of creditors other than micro enterprises and small enterprises	42.61	433.64	46.01	434.80
(ii) Other financial liabilities	230.52	219.56	230.52	219.56
(b) Current tax liabilities (net)	1.81	-	1.81	-
(c) Other current liabilities	0.65	7.84	0.66	7.93
Total current liabilities	278.15	661.04	281.56	662.29
Total liabilities	278.15	661.04	281.56	662.29
Total equity and liabilities	3,694.20	3,657.45	3,719.16	3,683.20

Page 2 of 4



Chandhaskar 2

FORTIS MALAR HOSPITALS LIMITED (CIN: L85110PB1989PLC045948)

Regd. Office: Fortis Hospital, Sector 62, Phase – VIII, Mohali-160062

Tel Numbers: 0172 5096001 & Tele Fax No : 0172 5096002

Website: www.fortismalarhospital.com; Email: secretarial.malar@malarhospitals.in

STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2025

Notes:

2. STANDALONE AND CONSOLIDATED STATEMENT OF CASH FLOWS

(Rs. in lakhs)

Particulars	Standalone		Consolidated	
	Six Months ended September 30, 2025	Six Months ended September 30, 2024	Six Months ended September 30, 2025	Six Months ended September 30, 2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Cash flows from operating activities				
Profit before tax for the year	445.88	3.53	442.93	2.38
<i>Adjustments for:</i>				
Interest income	(104.24)	(138.95)	(104.24)	(138.95)
Liabilities/ provisions no longer required written back	(408.20)	-	(408.20)	-
	(66.56)	(135.42)	(69.51)	(136.57)
Working capital adjustments:				
Increase in other assets and other financial assets	(3.07)	(3.80)	(3.07)	(3.80)
Decrease in trade and other receivables	-	-	(2.50)	-
Decrease / (Increase) in trade payables	19.73	(24.25)	21.98	(24.52)
Increase / (Decrease) in other liabilities and other financial liabilities	3.77	(81.83)	3.68	(103.22)
Cash used in operations	(46.13)	(245.30)	(49.42)	(268.11)
Income taxes refund / (paid) (net)	(24.43)	338.12	(24.43)	338.09
Net cash generated from / (used in) operating activities (A)	(70.56)	92.82	(73.85)	69.98
Cash flows from investing activities				
Purchase consideration received from sale of business	-	145.58	-	145.58
Dividend from equity investment	-	180.00	-	-
Proceeds from bank deposits (net)	75.75	-	75.75	-
Bank balances not considered as cash and cash equivalents	(87.40)	(3,127.13)	(87.40)	(3,127.90)
Interest received	92.65	166.05	92.65	166.82
Net cash (used in) / generated from investing activities (B)	81.00	(2,635.50)	81.00	(2,815.50)
Cash flows from financing activities				
Dividend payment	-	(7,965.24)	-	(7,965.24)
Net cash used in financing activities (C)	-	(7,965.24)	-	(7,965.24)
Net (decrease) / increase in cash and cash equivalents (A+B+C)	10.44	(10,507.92)	7.15	(10,710.76)
Cash and cash equivalents at the beginning of the year	10.80	10,528.78	20.24	10,740.88
Cash and cash equivalents at the end of the year	21.24	20.86	27.39	30.12

Page 3 of 4



Chandrasekar R

FORTIS MALAR HOSPITALS LIMITED (CIN: L85110PB1989PLC045948)

Regd. Office: Fortis Malar Hospital, Sector 62, Phase – VIII, Mohali-160062

Tel Numbers: 0172 5096001 & Tele Fax No : 0172 5096002

Website: www.fortismalarhospital.com; Email: secretariatmalar@malarhospitals.in

STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2025

Notes:

- 3 The unaudited standalone and consolidated financial results of Fortis Malar Hospitals Limited ("the Company") for the quarter and six months ended September 30, 2025 has been reviewed by the Audit and Risk Management Committee and subsequently approved by the Board of Directors at their respective meeting held on November 6, 2025. The above results have been subjected to limited review by the Statutory auditors of the Company. The auditors have issued an unmodified review report.
- 4 These unaudited financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 5 The consolidated financial results include the financial results of the Company Fortis Malar Hospitals Limited and the financial results of its subsidiary company Fortis Healthcare Research Foundation (Formerly known as Malar Stars Medicare Limited), (collectively known as "Group").
- 6 The Company is engaged in the Healthcare Services, which in the context of Indian Accounting Standard (Ind AS) 108 - Operating Segments is considered as the only reportable segment of the Company. Also refer note 7 below.
- 7 During the year ended March 31, 2024, the Company had entered into Business Transfer Agreement ("BTA") with MGM Healthcare Private Limited ("MGM") for the sale of its business operations pertaining to Malar Hospital, as a going concern, on a slump sale basis. Post the slump sale transaction, the Company ceases to have any business operations. Currently, the management of the Company has no visibility of commencing any new business operations in the future and the Company's management and Board of Directors, in consultation with its legal advisors/ merchant bankers, is evaluating various corporate restructuring options for the future possible course of actions for the Company and is progressing with the finalisation of plan.

The Company's cash and cash equivalent and other bank balances (~Rs 3,246.70 lakhs) would be sufficient to settle its obligations as and when they fall due. Based on the current cash position and projected cash flows, the Company believes that it would be able to meet its financial obligations for the foreseeable future such as ongoing expenses for running the Company, resolving medico legal cases (claim amount: ~Rs 625.92 lakhs), VAT appeals (tax demand: ~Rs 254.93 lakhs), GST appeal (tax demand: ~Rs 5.96 lakhs) and Income tax appeal (tax demand ~Rs 150.61 lakhs) which are being contested. As a matter of abundant caution these details are being disclosed herein and should not be construed in any manner as admission of any liability or breach. Any financial exposure in respect of medico legal cases, VAT appeals, GST appeal and Income tax appeal are currently estimated and assessed by management as remote. Accordingly, these standalone and consolidated financial results have been prepared on a going concern basis.

- 8 During the previous year, the Company had received show cause notices totaling to Rs 22,535.42 lakhs from GST authority for the period from July, 2017 to March, 2024, wherein they had proposed to levy GST on various items including depreciation, employee salaries, exempt healthcare services, interest expenses, trade payables, etc., on which either GST is not leviable or on which GST had already been paid, and also GST authority had proposed to disallow GST input tax credit, which had never been claimed by the Company. Subsequent to issuance of show cause notices, Company has received adjudication order against show cause notice for first two years i.e. for the period from July, 2017 to March, 2018, and financial year 2018-19 whereby as against proposed demand of Rs 7,231.32 Lakhs for the said periods, demand has been reduced to Rs 5.96 Lakhs. Consequently, the proposed demand of the show cause notices for the period from July 2017 to March 2024 stands reduced to Rs 15,310.06 lakhs. The company has filed an appeal against the aforementioned adjudication order of July 17 to March 18 of Rs 4.82 lakhs on May 2, 2025. Whereas the order for FY 2018-2019 of Rs 1.14 Lakhs which has been received on October 31, 2025, is being analysed and the next course of action will be decided accordingly.

With reference to the show cause notices for the balance period from April 2019 to March 2024, the Company firmly believes that these notices are not tenable. This position is based on a comprehensive management assessment, view of a leading tax consultant, and the grounds on which the adjudication order was previously passed for first two years. The Company has strongly objected to the issuance of these show cause notices and has submitted appropriate and detailed responses in this regard. In view of the above, the Company considers the possibility of any financial exposure arising from these matters to be remote.

- 9 During the quarter ended June 30, 2025, Malar Stars Medicare Limited, the subsidiary company, filed an application with the Ministry of Corporate Affairs, for conversion into a Section 8 Company, as per the provisions of the Companies Act, 2013. The application has been approved by Ministry of Corporate Affairs and is effective from May 14, 2025. Consequently, the name of the subsidiary Company has also been changed from 'Malar Stars Medicare Limited' to 'Malar Star Medicare'. Further, the name of the subsidiary Company has been changed from 'Malar Star Medicare' to 'Fortis Healthcare Research Foundation' with effect from August 26, 2025.
- 10 Pursuant to the notification dated June 11, 2025 issued by the Government of Tamil Nadu, regarding the revision of minimum wage rates, the Company has reversed the provision of Rs 408.20 lakhs towards earlier minimum wages payable. The provision written back has been considered as other income in the standalone and consolidated financial results for the quarter ended June 30, 2025.
- 11 In light of the acquisition of the controlling stake of FHL by Northern TK Venture Pte Limited ("NTK") a wholly owned subsidiary of IHH Healthcare Berhad, Malaysia, a mandatory open offer got triggered for acquisition by NTK of up to 4,894,308 fully paid up equity shares of face value of INR 10 each in the Company, representing 26% of the paid-up equity shares of the Company at a price of Rs. 60.10 per share ("Malar Open Offer") in December 2018. However, in view of order dated December 14, 2018 passed by Hon'ble Supreme Court wherein it was specified that status quo with regard to sale of the controlling stake in Fortis Healthcare Limited to IHH Healthcare Berhad, Malaysia be maintained ("Status Quo Order"), the Mandatory Open offer was kept in abeyance. The Hon'ble Supreme Court vide its final judgment dated September 22, 2022 ("2022 Judgment") disposed of the petitions with certain directions to the Hon'ble High Court of Delhi. Basis legal advice, it is understood that pursuant to the 2022 Judgment, the Status Quo Order, being an interim order, ceases to exist and stands merged with the 2022 Judgment.
- On October 16, 2025, the Company made a Disclosure in respect of the announcement made by IHH Healthcare Berhad ("IHH") dated October 16, 2025 on the Malaysian Stock Exchange (i.e. Bursa Malaysia) regarding the Malar Open Offer (open offer price was revised from the original open offer price of INR 60.10 (Indian Rupees Sixty and Ten Paise only) per Equity Share to INR 17.60 (Indian Rupees Seventeen and Sixty Paise only), in accordance with the requirements of the SEBI (SAST) Regulations) Basis announcement made by IHH, it is understood that Malar Open Offer has now been recommenced and the same is expected to be completed by November 26, 2025 as per the Schedule of major activities of the Offer, filed by IHH.

- 12 These financial results are available on the BSE website (www.bseindia.com) and on the Company's website (www.fortismalarhospital.com).



By Order of the Board
Fortis Malar Hospitals Limited
CIN: L85110PB1989PLC045948

Chandrasekar R
Whole Time Director
DIN : 09414564

Place : Bengaluru
Date: November 6, 2025